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"Quem sabe concentrar-se numa coisa e 
insistir nela como único objetivo, obtém 
ao fim, a capacidade de fazer qualquer 
coisa."  
Gandhi 
	RESUMO 
 
Introdução: As células mesenquimais indiferenciada da medula óssea (CMIMO) são consideradas 
fonte promissora para terapia celular, embora sua regulação epigenética não seja totalmente 
compreendida. O RG108 bloqueia o sítio ativo das enzimas que metilam o DNA, as DNA-
metiltransferases (DNMTs). Objetivo: Melhor compreender a biologia básica das CMIMO e 
efeitos do RG108 e da consequente inibição das DNMTs, nas modificações epigenéticas 
globalmente e em genes específicos da maquinaria epigenética. Além disso, foram avaliados genes 
envolvidos na manutenção do estado multipotente das CMIMO. Métodos: As células foram 
distribuídas em grupos e tratadas durante 3 dias: DMEM – células cultivadas em meio de cultura 
padrão; Dimetilsulfóxido (DMSO/veículo do RG108) – células cultivadas em DMEM+DMSO; 
RG108 – células cultivadas em DMEM+RG108 (50µM) e os efeitos foram testados, avaliando-se 
viabilidade, tempo de duplicação e apoptose celular. A metilação/hidroximetilação global, atividade 
das desmetilases e das DNMTs e níveis da proteína DNMT1 foram avaliados por ensaios 
colorimétricos. Os níveis de transcritos dos genes DNMT1, Ten-eleven-translocation-(TET) -1 e 
POU5F1-POU-class-5-homeobox-1-(OCT4) foram quantificados pela reação em cadeia da 
polimerase (qPCR) e os níveis de metilação/hidroximetilação dos genes DNMT1, DNMT3B e 
NANOG-Homeobox (NANOG) foram avaliados por qPCR, precedidos pela glicosilação da 5-
hidroximetilcitosina e digestão com enzimas de restrição. Resultados: O RG108 não reduz  
viabilidade celular ou induz a morte celular por apoptose e não afeta a taxa de proliferação celular. 
Globalmente, o RG108 diminui a metilação do DNA (p ≤ 0,05), sem modulação dos níveis de 
hidroximetilação. Houve diminuição na atividade das DNMTs para os grupos DMSO e RG108, 
comparados ao grupo DMEM (p ≤ 0,05); antagonicamente, houve aumento na atividade das 
desmetilases para os grupos DMSO e RG108, em comparação ao DMEM (p ≤ 0,05), sem mudança 
nos níveis da proteína DNMT1. Os níveis de RNAm para o gene DNMT1 foram reduzidos para os 
grupos DMSO e RG108 (p ≤ 0,05) e o grupo tratado com RG108 apresentou níveis aumentados de 
RNAm para os genes TET1 (p ≤ 0,05) e OCT 4 (p ≤ 0,05), comparando-se ao DMEM. Não houve 
modulação nos níveis de metilação/hidroximetilação do gene DNMT1. Entretanto, um aumento nos 
níveis de metilação do gene DNMT3B foi observado nos grupos DMSO e RG108, comparados ao 
DMEM (p ≤ 0,05), sem modulação nos níveis de hidroximetilação. Em contrapartida, o gene 
NANOG respondeu diminuindo os níveis de hidroximetilação do DNA para o grupo RG108 (p ≤ 
0,05), sem modulação nos níveis de metilação do DNA. Conclusão: O RG108 é um agente 
desmetilante seguro, capaz de modular a atividade das DNMTs e desmetilases, nas CMIMO. Essa 
modulação estimulou mudanças globais no DNA e em transcritos de genes específicos. Entretanto, 
não houve modulação para o gene ou a proteína DNMT1, embora tenha sido observada para o gene 
DNMT3B e também para o gene NANOG, modulado em seus níveis de hidroximetilação. O 
modulador epigenético RG108 e a consequente inibição da DNMT1 promovem mudanças nos 
genes da maquinaria epigenética e em genes relevantes para a manutenção das CMIMO em estado 
indiferenciado. Interessantemente, o DMSO também desencadeou modulação, entretanto, esta 
modulação foi restrita aos genes da maquinaria epigenética. 
 
Palavras-chave: epigenômica, células mesenquimais estromais, DNA (citosina-5-) metiltransferase, 
hidroximetil e formil transferase, metilação, RG108.   
 
 
	ABSTRACT 
 
Background: The human bone marrow-derived mesenchymal stem cells (hBMMSCs) have been 
considered a promising source for cellular therapy, althoug their epigenetic regulation is not well 
understood. The RG108 is a DNA methyltransferase (DNMT) inhibitor, designed to block the 
active site of the DNMTs enzymes. Objective: This study was designed to better comprehend the 
basic biology of the hBMMSCs and the effects of the RG108 and the DNMT1 inhibition, in the 
epigenetic global levels and in specific genes from epigenetic machinery; in addition, core genes 
involved in maintaining the hBMMSCs in the undifferentiated state were also evaluated. Methods: 
The hBMMSCs were distributed in groups and treated during 3 days: DMEM – cells were cultivated 
in complete culture medium; DMSO (RG108 vehicle) – cells were cultivated in complete culture 
medium/DMSO; RG108 -  cells were cultivated in complete culture medium/RG108 (50 µM) and 
the RG108 effect was assessed through cell viability, population doubling time and apoptosis 
assays. The global DNA methylation and hydroxymethylation levels, the demethylases and the 
DNMTs activities and the DNMT1 protein levels were assessed by colorimetric assays. The 
DNMT1, TET1 and OCT4 genes transcript levels were quantified by quantitative real-time 
polymerase chain reaction (qPCR) and the DNMT1/3B/NANOG genes 
methylation/hydroxymethylation status were evaluated by qPCR, preceded by glucosylation of 5-
hydroxymethylcytosine and restriction enzymes digestion. Results: The RG108 did not reduce the 
cell viability or induce cellular death by apoptosis and the proliferation rate in vitro was not affected. 
At global levels, the RG108 significantly decreased methylation status (p ≤ 0.05), without 
modulation at hydroxymethylation levels. There was a significant decrease in the DNMTs activity 
levels for DMSO and RG108 treated cells, comparing to the DMEM group (p ≤ 0.05); in an 
antagonistic way, the demethylases activity levels were found to be increased for the DMSO and 
RG108 groups, comparing to the DMEM group (p ≤ 0.05), without changing in the DNMT1 protein 
levels. The DNMT1 mRNA levels were decreased for DMSO and RG108 groups (p ≤ 0.05) and 
the RG108 treated cells showed an increase in the TET1 mRNA levels (p ≤ 0.05) and OCT4 mRNA 
levels (p ≤ 0.05), comparing to the DMEM group. There was no modulation in the DNMT1 gene 
methylation/hydroxymethylation levels; however, a significant increase in the methylation levels 
of DNMT3B was observed for the DMSO and RG108 groups, comparing to the DMEM group (p 
≤ 0.05) and no modulation in the hydroxymethylation levels was found. On the other hand, the 
NANOG gene have responded significantly decreasing the hydroxymethylation levels for the 
RG108 group (p ≤ 0.05), without modulation in its methylation levels. Conclusions: The RG108 
is a safe demethylating agent, with the ability of modulating the DNMTs and demethylases 
activities, in the hBMMSCs. This modulation was able to trigger changes at global status and 
transcription levels; however, no modulation was found at DNMT1 protein and gene levels; yet it 
was observed at DNMT3B gene instead, also reflecting at NANOG gene, which was modulated at 
hydroxymethylation levels. The epigenetic modulator RG108 and the DNMT1 inhibition are 
capable of promoting changes in the epigenetic machinery genes and in relevant genes for 
maintaining the hBMMSCs in an undifferentiated state. Interestingly, the DMSO was also capable 
of triggering modulation, however it was restricted to the epigenetic machinery genes.  
	
Keywords: Epigenomics, Mesenchymal Stromal Cell, DNA (Cytosine-5-)-Methyltransferase, 
Hydroxymethyl and Formyl Transferases, Methylation, RG108 
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1 INTRODUÇÃO 
 
Células mesenquimais indiferenciadas, encontradas em vários tecidos do corpo humano 
e que podem ser obtidas de pacientes adultos, possuem capacidade de auto renovação e podem 
se diferenciar em vários tipos celulares, como osteoblastos, condrócitos, adipócitos e secretar 
fatores de crescimento que favorecem o processo de regeneração tecidual (Ranganath et al., 
2012; Salem et al., 2010; Lin et al., 2015).  Essas habilidades tornam-nas importante para a 
terapia celular regenerativa (Ren at al., 2012). No campo da Odontologia, principalmente na 
periodontia, a regeneração do periodonto alterado pela doença periodontal é um grande desafio. 
Diferentes abordagens têm sido propostas, mas a quantidade de tecido regenerado 
frequentemente é limitada e imprevisível (Lin et al., 2015). Como consequência, uma das 
tendências atuais das pesquisas é o desenvolvimento de técnicas baseadas em terapias com 
células para a regeneração periodontal (Hynes et al., 2012). 
Grandes candidatas às técnicas de terapia celular, as células mesenquimais 
indiferenciadas da medula óssea são as mais estudadas e vários autores já demostraram que 
essas células são capazes de induzir a regeneração periodontal caracterizada pela nova 
formação de cemento, osso alveolar e ligamento periodontal em experimentos com defeitos 
periodontais em ratos, coelhos, mini-pigs e cachorros (Rios et al., 2011; Hynes et al., 2012; Lin 
et al., 2015). O avanço no entendimento da regulação epigenética em células mesenquimais 
indiferenciadas poderá trazer benefícios futuros na regeneração periodontal. 
Epigenética é o estudo das alterações na regulação do gene que não causam mudanças 
na sequência do DNA. O genoma pode ter mudanças funcionais relevantes que não alteram a 
sequência de nucleotídeo (Seo et al., 2015). Alterações epigenéticas são complexas e envolvem 
modificações na cromatina, que é uma unidade funcional composta pela molécula de DNA e as 
proteínas que se associam ao DNA, as histonas. Estas modificações são divididas em várias 
categorias, incluindo modificações no DNA, como a metilação da citosina e, mais 
recentemente, descoberta a hidroximetilação do DNA. Nas histonas, podem ocorrer 
modificações pós-traducionais, como a metilação, ubiquitinação, fosforilação e acetilação que 
estão relacionadas a alterações na conformação da cromatina e ainda as vias mediadas por RNA 
não codificante (Cheng et al., 2015).  
A metilação do DNA ocorre simetricamente nas duas fitas da molécula e é a 
modificação da cromatina mais conhecida (Seo et al., 2015), consistindo na adição do grupo 
metil no carbono 5 da citosina, transformando-a em 5-metilcitosina (5mC). É uma marca 
epigenética comum e frequentemente encontrada nas sequências CpGs e, quando localizada na 
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região promotora de um gene, é considerada uma marca repressiva (Laird, 2010). Os padrões 
de metilação do DNA estão relacionados à estrutura da cromatina. Um DNA desmetilado está 
tipicamente associado a uma conformação ativa da cromatina enquanto que o DNA metilado 
está associado a uma cromatina inativa (Eilertsen et al., 2008). A metilação do DNA é catalisada 
pelas enzimas DNA metiltransferases (DNMTs) 1, 2, 3A, 3B e 3L, utilizando S-adenosil-L-
metionina (SAM) como doador do grupo metil. No mecanismo direto, a metilação nos CpGs é 
capaz de modular e/ou silenciar a expressão do gene, alterando a acessibilidade do DNA aos 
fatores de transcrição (Turek-Plewa and Jagodziński, 2005; Yang et al., 2010).	As DNMT1 são 
as enzimas responsáveis pela manutenção do padrão de metilação nas novas cópias de DNA 
durante a replicação, que devem ser metiladas de uma maneira muito precisa para que se 
mantenha o padrão original de metilação do DNA (Turek-Plewa e Jagodziński, 2005). Acredita-
se que estejam estreitamente relacionadas à forquilha de replicação na fase S do ciclo celular 
(Xu et al., 2010). As enzimas DNMT3A e 3B são responsáveis pela metilação de novo, 
mecanismo no qual ocorre a adição de um novo radical metil onde antes não havia, e a molécula 
de DNA adquire um novo padrão de metilação (Turek-Plewa e Jagodziński, 2005). 
 Outra modificação epigenética importante é a hidroximetilação do DNA, realizada 
pelas enzimas da família ten-eleven-translocation (TET) 1, 2 e 3, que oxidam 5-metilcitosina 
em 5-hidroximetilcitosina, que é o primeiro passo para a desmetilação do DNA (Tahiliani et 
al., 2009; Santiago et al., 2014). Uma cromatina hidroximetilada está associada a uma 
arquitetura mais permissiva ao acesso dos fatores de transcrição e, portanto, à expressão gênica. 
Fatores de transcrição como OCT4 (POU5F1 - POU class 5 homeobox 1) e NANOG 
(NANOG Homeobox) são reguladores essenciais no desenvolvimento inicial e na identidade 
das células-tronco embrionárias (Boyer et al., 2005). Um estudo recente em células 
mesenquimais indiferenciada derivada da medula óssea de humanos observou a diminuição da 
expressão de DNMT1, via knockdown de OCT4 e NANOG (Tsai et al., 2012). Os autores 
concluíram que a manutenção das propriedades de células-tronco das células mesenquimais 
indiferenciadas era mediada pelos genes OCT4 e NANOG, por meio da expressão de DNMT1. 
Foi demonstrado que esta regulação é direta, pois ocorre a ligação dos fatores de transcrição 
OCT4 e NANOG ao promotor do gene DNMT1	 (Boyer et al., 2005; Tsai et al., 2012). No 
entanto, o papel das enzimas da maquinaria epigenética nas células mesenquimais 
indiferenciadas da medula óssea precisa ser melhor investigado. 
Moduladores epigenéticos têm sido utilizados na modulação experimental da regulação 
gênica. Dentre os vários existentes, o RG108 [2-(1,3-dioxi-1,2-dihidro-2isoindol-2-il)-3-(1H-
indol-3-yl) ácido propanoico é um inibidor de DNMTs, desenvolvido por Brueckner e 
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colaboradores, 2005 a partir do domínio catalítico da DNMT1 humana descoberto por  
Siedlecki et al. 2003 (Gros et al., 2012). Testes subsequentes revelaram que o RG108 bloqueia 
eficientemente a metilação do DNA em células tumorais. Experimentos adicionais também 
revelaram uma significativa desmetilação dependente do RG108 e a reativação de genes 
supressores de tumores epigeneticamente silenciados.  Stresemann e colaboradores em 2006, 
avaliaram a citotoxicidade do RG108 e mais 5 outros inibidores de DNMTs. Embora o RG108 
não tenha sido o inibidor de DNMTs que mais reduziu os níveis de metilação do DNA, o 
composto não demonstrou indicações de citotoxicidade. Além disso, o RG108 foi o único capaz 
de inibir diretamente a DNMT recombinante purificada. Entretanto, existem poucos estudos 
utilizando o RG108 em células mesenquimais indiferenciadas derivadas da medula óssea. Oh 
e colaboradores (2014), concluíram que RG108 foi capaz de reduzir consideravelmente a 
metilação na região promotora dos genes. Assim, uma dose adequada de RG108 pode melhorar 
a capacidade de migração celular, o que pode proporcionar uma melhor eficácia na terapia 
celular. 
 Apesar da especificidade do RG108 em inibir as DNMTs, o seu efeito na maquinaria 
epigenética ainda não foi respondido. Além disso, a biologia básica das células mesequimais 
indiferenciadas não é completamente conhecida. Diante do exposto, como o RG108 é tido na 
literatura como um modulador epigenético promissor a ser utilizado na terapia celular, o 
objetivo desse estudo é investigar a habilidade do RG108 em estimular mudanças nos padrões 
epigenéticos globais e em genes específicos da maquinaria epigenética e relacionados à 
multipotencialidade celular, nas células mesenquimais indiferenciadas da medula óssea. 
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2 ARTIGO 
 
RG108 PROMOTES CHANGES IN DNMTS AND TETS ACTIVITIES 
CONTRIBUTING, THROUGH OCT4 EPIGENETIC ACTIVATION, TO THE 
MAINTENANCE OF MESENCHYMAL CELLS MULTIPOTENCY 
 
Manuscrito submetido à revista Scientific Reports (Anexo 1) 
 
Assis R I F1, Wiench M2, Silvério K G1, da Silva R A3, 
Sallum E A1, Casati M Z1, Nociti Jr F H1, Andia D C1,4* 
 
1 Division of Periodontics, Department of Prosthodontics and Periodontics, Piracicaba Dental 
School, University of Campinas-UNICAMP, Piracicaba, São Paulo, Brazil. 
 
2 School of Cancer Sciences and School of Dentistry; College of Medicine and Dentistry, 
University of Birmingham, Birmingham, UK. 
 
3 Department of Chemistry and Biochemistry, Biosciences Institute, São Paulo State University, 
Botucatu, São Paulo, 18618-970, Brazil.  
 
4 Division of Epigenetics, School of Dentistry, Health Science Institute, Paulista University, 
São Paulo, Brazil. 
 
*Corresponding author 
Denise Carleto Andia 
Paulista University – UNIP 
Health Science Institute, School of Dentistry, Division of Epigenetics  
Dr. Bacelar Av, 1212, Vila Clementino, São Paulo, SP, 04026-002 – Brazil 
denise@andia.com.br    +55 (11) 5594 3207 
 
Financiamento: Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/02160-0, 
2013/09650-8).  
 
 
 
	 17	
ABSTRACT  
 
Human bone marrow-derived mesenchymal stem cells (hBMMSCs) are important for tissue 
regeneration but their epigenetic regulation is not well understood. Here we investigate the 
ability of RG108, which blocks the active site of DNA methyltransferases (DNMTs), to induce 
epigenetic changes at both global and gene- specific levels in order to trigger the hBMMSCs 
multipotency. RG108 treatment did not affect hBMMSCs viability, apoptosis and proliferation 
rates while leading to significant changes in epigenetic regulation and machinery. The DNMTs’ 
activity was decreased, associated with a global reduction in DNA methylation. Furthermore, 
DNMT1/DNMT3B transcript levels were downregulated. This additional mechanism could be 
controlled by pluripotency genes OCT4/NANOG/TET1. We report RG108 to trigger DNA 
methylation loss at these genes accompanied by their upregulation. Despite the increase of 
demethylases activity and TET1 expression the global hydroxymethylation level was not 
affected by RG108 alone and the observed decrease was due to DMSO (RG108 vehicle). The 
DMSO-triggered changes were also detected at mRNA and protein levels of investigated genes. 
We propose that RG108 could be used for epigenetic modulation of hBMMSCs without 
affecting their viability and ultimately promoting multipotency markers. Our data also support 
the existing evidence that DMSO has a potential to modulate epigenetic mechanisms.  
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INTRODUCTION 
 
 The promising results of clinical tests using human mesenchymal stem cells (hMSCs) 
make them a relevant source for cellular therapy applications in a wide range of diseases as 
well as in regenerative medicine. However, the epigenetic regulation underlying hMSCs is not 
well understood. Pluripotency genes, such as POU5F1-POU- class-5-homeobox-1 (OCT4) and 
NANOG-Homeobox (NANOG), are expressed in hMSCs1,2 and constitute the core regulatory 
network that suppresses differentiation- associated genes, thereby maintaining the pluripotency 
of cells3. OCT4/NANOG genes were demonstrated to be involved in inhibiting spontaneous 
differentiation in MSCs, via regulating DNA methytransferase (DNMT) -1, an epigenetic 
machinery enzyme4. Ten eleven translocation (TET) -1, an enzyme involved in active DNA 
demethylation, is a NANOG protein partner and both proteins are associated with maintenance 
of pluripotency and lineage commitment in embryonic stem cells5. TET1 is also recruited by 
NANOG to enhance the expression of OCT45. Although recent investigations have discovered 
and confirmed fundamental mechanisms involved in the maintenance of the undifferentiated 
cell state, few studies have been focused on hMSCs.  
Epigenetics is defined as the study of mitotically and/or meiotically heritable changes 
in gene function that cannot be explained by DNA sequence change6. Chemical changes in the 
DNA molecule and histone proteins may act by modifying the chromatin architecture and 
changing the accessibility of transcription factors to gene regulatory elements. Therefore, these 
modifications are essential for either maintaining cells in an undifferentiated state or directing 
them towards cell fate specification. Some of the known epigenetic changes in the DNA 
molecule are methylation and hydroxymethylation. DNMT enzymes are implicated in the DNA 
methylation mechanism and all evidence indicates that DNMT1 enzyme acts as a maintenance 
methyltransferase, operating at the replication fork7. DNMT3B enzyme is involved in the de 
novo acquisition of DNA methylation status, introducing cytosine methylation at previously 
unmethylated CpG sites7,8. On the other hand, the oxidation of methylcytosine (5mC) to 
hydroxymethylcytosine (5hmC) has been shown to underlay the DNA demethylation 
mechanism and TET enzymes are responsible for catalysing this reaction9. Generally, 
unmethylated DNA is associated with permissive and open chromatin architecture, whereas the 
presence of nucleosomes and condensed chromatin is related to methylated DNA. However, 
the specific roles of epigenetic machinery enzymes in hMSCs require investigation.  
Since epigenetic control is closely related to gene regulation, epigenetic modulators 
have been used to affect gene expression patterns and cell fate. RG108 [2- (1,3-dioxo-1,3-
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dihydro-2Hisoindol-2-yl)-3-(1H-indol-3-yl) propanoic acid] is a compound specifically 
designed to block the active site of DNMTs10. The confirmed ability of reactivate several 
tumour suppressor genes and the lack of cell toxicity10,11 make RG108 a good candidate for 
epigenetic modulation therapies. Several investigations have used RG108 for studying 
mechanisms involved in human disorders as well as in physiological conditions12-18. However, 
only few studies have tested this compound in hMSCs. In 2015, Oh et al. investigated the 
hypothesis that RG108 could provide beneficial efficacy in treating ageing-related diseases by 
restoring the altered methylation pattern19. In the follow up study, they investigated if excessive 
DNMTs’ expression found in amyotrophic lateral sclerosis could be controlled by RG10820. 
The authors suggested that RG108 may provide a better efficacy of hMSCs in stem cells 
therapy, since the cell function was restored with an improvement in their stem cell potency, 
cell migration, oxidative stress protection and senescence.  
Although RG108 was specifically designed to target DNMT enzymes, its effect on the 
epigenetic machinery itself as well as genome-wide is still unknown. In addition, the hMSCs 
epigenetics is not completely understood. Therefore, in this study we investigate the ability of 
RG108 to trigger global changes in DNA methylation and hydroxymethylation levels, in 
addition to gene-specific effects on epigenetic machinery and markers of hMSCs multipotency. 
The study aims at better understanding the epigenetic regulation of hMSCs and explores the 
possibility of using RG108 in hBMMSCs-based cell therapies.  
 
 
RESULTS 
 
Effect of RG108 on viability and apoptosis in human bone marrow-derived mesenchymal 
stem cells (hBMMSCs)  
To determine the optimal RG108 treatment in hBMMSCs, several concentrations (50 
µM, 100 µM and 200 µM) of the compound have been tested at day 7 (Figure 1A). The 
metabolic activity was the least affected when cells were treated with 50 µM of the compound. 
After choosing 50 µM as optimal concentration, the hBMMSCs viability was again evaluated 
at day 3. The results confirmed that 50 µM of RG108 does not affect the viability of hBMMSCs 
when compared to control cells (DMEM only) and cells cultured in the presence of RG108 
vehicle, DMSO (Figure 1B). Similarly, the population doubling time (PDT) of RG108-treated 
cells did not differ from the control cells (43.73h and 43.23h, respectively), demonstrating that 
3 days of 50 µM RG108 treatment did not affect the ability of hBMMSCs to proliferate in vitro 
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(Figure 1C). In addition, an apoptotic assay was performed and again no differences were 
observed, with DMEM group presenting 98.69 % of intact cells and DMSO and RG108 groups 
presenting 98.06 % and 99.22 %, respectively (Figure 1D-F).  
 
Effect of RG108 on global DNA methylation and hydroxymethylation levels  
The global DNA methylation was assessed by a colorimetric assay and demonstrated a 
statistically significant decrease, approximately 25%, in the methylation levels in RG108 group, 
compared to DMEM group (p ≤ 0.05). Demethylation was also observed when cells were 
treated with DMSO however to a much smaller extent and there were no statistical differences 
when comparing DMSO treated cells with DMEM and RG108 groups (Figure 2A). Next a 
colorimetric assay was used to analyse DNA hydroxymethylation levels. Both RG108 and 
DMSO treated cells showed around 22% decrease in the global hydroxymethylation levels 
comparing to the DMEM group; however, these differences were not statistically significant 
(Figure 2B).  
 
RG108 reduces the DNMTs activity and increases the TETs activity  
Since the RG108 compound was specifically design to block the DNMTs active site and 
a decrease in the global methylation levels was observed, the DNMTs activity was analysed 
after cell nuclear protein extracts were obtained. There was a significant reduction in the 
DNMTs activity levels for both RG108 and DMSO treated cells, however the decrease was 
much larger for RG108 (70% vs. around 35% for DMSO group) (Figure 3A). The demethylases 
(TETs) activity levels were also evaluated and a significant increase to a similar extent was 
observed for both DMSO and RG108 treated cells (Figure 3B).  
 
Effect of RG108 on the DNMT1 protein levels  
There was no statistically significant difference amongst the groups regarding the 
DNMT1 protein levels (p > 0.05) (Figure 3C), although a decrease around 30% for both DMSO 
and RG108 groups was observed when compared to the control cells.  
 
RG108 decreases DNMT1 and DNMT3B and increases TET1 and OCT4 mRNA levels  
To further investigate whether the decrease in the DNMTs activity levels was correlated 
with mRNA levels, the DNMT1 and DNMT3B genes transcripts were analyzed. Results 
demonstrated a decrease in the transcript levels for both genes, with DMSO and RG108 treated 
cells being significantly different from DMEM group. Specifically, DNMT1 expression levels 
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were decreased by 70-fold in the RG108-treated cells when compared to the DMEM group. On 
the other hand, a significant increase in TET1 and OCT4 mRNA levels was observed in RG108-
treated cells (p ≤ 0.05), when compared to DMSO and DMEM groups (Figure 4).  
 
RG108-induced epigenetic modulation at specific genes  
Methylation and hydroxymethylation changes at DNMT1, DNMT3B, NANOG and 
OCT4 genes were evaluated by quantitative-methylation-PCR assay method. No changes in the 
methylation and hydroxymethylation patterns were observed at the DNMT1 gene analyzed 
region (Figure 5A). However, a statistically significant increase in the DNMT3B gene 
methylation levels was observed for DMSO and RG108 groups, when compared to the DMEM 
group (p ≤ 0.05) (Figure 5B). On the other hand, the NANOG gene has demonstrated a 
statistically significant decrease in the hydroxymethylation levels for the RG108 group (p ≤ 
0.05) (Figure 6A). Furthermore, the methylation and hydroxymethylation levels at the OCT4 
gene region were significantly reduced for the RG108 group (p ≤ 0.05), when compared to the 
DMEM group and the methylation results were also significantly different between the RG108 
and DMSO groups (Figure 6B).  
 
 
DISCUSSION 
 Improvement of cell therapy efficacy is one of the main goals in regenerative medicine 
and hMSCs have been extensively studied for this purpose. However, their epigenetic 
regulation remains to be elucidated. Epigenetic mechanisms contribute significantly to 
development, phenotype changes and cell fate specification. Therefore, understanding the 
hMSCs epigenetics is crucial for planning and executing stem cell- based therapies. This study 
aimed to better understand epigenetic regulation in hMSCs by investigating the effects of 
DNMT inhibitor, RG108, on transcription of pluripotency and epigenetic machinery genes. The 
results point to epigenetic modulation at both global and gene-specific levels leading to 
upregulation of pluripotency-related genes and, probably through a secondary mechanism, to 
changes in genes involved in methylation/demethylation mechanisms.  
There are two main groups of epi-drugs affecting the DNMTs activity, the nucleoside 
and non-nucleoside inhibitors. RG108 is a non-nucleoside inhibitor that efficiently blocks the 
DNMTs active site and shows fewer side effects than other inhibitors10. Importantly, recent 
investigations have suggested that RG108 may provide increased hMSCs efficacy in stem cells 
therapy19,20. In the present study RG108, when used at 50 µM, showed lack of toxicity and did 
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not trigger cell death by apoptosis or changes in the cells ability to proliferate in vitro. These 
results are in line with previous observations reported for hBMMSCs19,20. On the other hand, 
Graça et al. observed a significant and dose-time dependent growth inhibition and induction of 
apoptosis, when human prostate cancer cells were treated with RG10814 at concentrations 
similar to these used in the present study. We also observed an adverse effect on cell viability, 
however, in much higher RG108 concentrations of 400 µM, 800 µM and 1.6 mM (decrease of 
24%, 40% and 50%, respectively, data not shown). RG108 effects are therefore highly cell 
type-dependent, probably due to different epigenetic backgrounds in tested cells and this makes 
the comparison among studies difficult.  
hBMMSCs has never been subjected to global epigenomic analysis after RG108 
treatment. As expected, our results showed a decrease in the DNMTs activity and this was 
followed by a reduction in global DNA methylation levels. The observed decrease was 
approximately 25% in RG108 group and this result is higher than the 10% reported by Graça 
et al. in prostate cancer cell lines14. Although RG108 works primarily through blocking DNMTs 
catalytic site we also observed a large (55-fold) decrease in DNMT1 expression level which 
could further contribute to the loss of methylation. This result can be explained by mechanisms 
involving NANOG and OCT4 regulation as discussed later. In addition, we observed a decrease 
in both DNMT3B gene expression and increase in its promoter methylation although this effect 
was seen in both RG108 and DMSO groups. Downregulation of DNMT1 and DNMT3B genes 
was also reported in prostate cancer cells after RG108 treatment, however the authors did not 
consider the DMSO effect14. DNMT3B has been proposed as a ‘reader’ of higher-order 
chromatin structure leading to gene silencing through DNA methylation and as a barrier for cell 
reprogramming (iPS)21,22,23. The iPS reprogramming process requires an open chromatin state24 
and DNMT3B might suppress a decondensation process of the chromatin and then prevent the 
accessibility of the reprogramming factors to their target regions. Since RG108 has been used 
in iPS reprogramming, it is possible to infer that the observed increase in the methylation levels, 
possibly contributing to DNMT3B gene silencing, and the decrease in the transcript levels in 
the DNMT3B gene, might be the RG108/DMSO-induced secondary effect aiming to achieve 
an open chromatin state in hBMMSCs.  
It is possible the RG108 could also affect, through secondary mechanisms, the DNA 
hydroxymethylation levels and demethylases activity, but this has never been studied. In fact, 
after statistical analysis, the results of the present investigation did not show differences at DNA 
hydroxymethylation levels after 3 days of RG108 treatment. However, an increase in the 
demethylases activity as well as upregulation of TET1 expression was observed at this time 
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point which corroborates the hypothesis that the hydroxymethylation levels could be increased 
after longer treatment. This could further contribute to the global methylation loss, since TET 
enzymes take part in the conversion of 5mC to 5hmC.  
The role of TET enzymes in the DNA hydroxymethylation mechanism by catalyzing 
the conversion of 5mC to 5hmC, was discovered a few years ago9 and their role as an 
intermediate in demethylation is currently well accepted. However, the role of 5hmC in gene 
expression might not be restricted to a transitory intermediate in the hydroxymethylation 
pathway. Specifically, 5hmC modification might attract interaction with certain regulatory 
proteins25. In addition, TET1 protein was identified as a NANOG protein partner in embryonic 
stem cells5, where both proteins were shown to co-occupy genomic loci of genes associated 
with the maintenance of pluripotency and lineage commitment. Olariu et al., proposed a 
multiple-level model in which the regulatory network of OCT4, NANOG and TET1 includes 
positive feedback loops involving DNA-demethylation around OCT4 and TET1 promoters26. 
In the above investigation, the authors demonstrated that NANOG/TET1 complex regulates 
OCT4 and TET1 expression, while OCT4 regulates NANOG, OCT4 and TET1. Although the 
present investigation was performed in hBMMSCs, OCT4, NANOG and TET1 play similar 
roles to those in embryonic stem cells and are essential for epigenetic regulation of cell 
multipotentiality. Therefore, these genes were investigated in the present study and the results 
indeed showed modulation of the OCT4/NANOG/TET1 complex at DNA, mRNA and protein 
levels. Wei and Shen have previously observed low levels of OCT4 transcripts in hBMMSCs2, 
which were similar to OCT4 transcript levels in the DMEM group in the present study. 
Nonetheless, RG108 was capable of stimulating the OCT4 expression by 3-fold compared to 
the DMEM group, which correlated to changes in methylation and hydroxymethylation at 
OCT4 gene. In addition, changes involving DNA hydroxymethylation at the NANOG gene 
promoter were observed; adding the information that both OCT4 and NANOG genes were 
epigenetically modified by RG108 in hBMMSCs. It is possible that these changes lead to a 
more open and relaxed chromatin in the analyzed regions, aiming at upregulating their 
transcript level. Furthermore, it has been shown that OCT4 and NANOG can regulate DNMT1 
gene through direct binding to its promoter4 and the OCT4 transcription is regulated by DNA 
methylation through DNMT1 protein27. In the present investigation, a significant decrease in 
DNMT1 transcript levels was observed after 3 days of RG108 treatment. Taking together, the 
results demonstrate changes in the OCT4/NANOG/DNMT1 complex, showing modulation at 
transcript levels and epigenetic mechanisms after RG108 treatment.  
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Based on the obtained results and published data we propose a mechanism of RG108 action in 
hBMMSc which originates from a global decrease in DNA methylation leading to a local 
decrease of methylation levels at the promoters of OCT4, TET1 and possibly NANOG. These, 
in turn would upregulate their expression and OCT4/NANOG/TET1 are well known to promote 
cell pluripotency. In addition, downregulation of DNMT1 expression (possibly through a 
secondary mechanism which could involve OCT4 and NANOG) and a possible increase in 
demethylases activity (due to increase of TET1 expression) would further enhance global loss 
of methylation. The global loss of methylation could then promote a more permissive chromatin 
therefore reinforcing the state of multipotency in hBMMScs (Figure 7).  
Interestingly, DMSO also triggered changes at specific genes involved in the epigenetic 
regulatory mechanisms, although the multipotency gene markers were not affected. There are 
a few studies showing the role of DMSO in affecting epigenetic regulation. Yokochi and 
Robertson have demonstrated that DMSO-mediated stimulation of DNMT3A activity depends 
on the specific interactions between DMSO and DNA and DMSO and AdoMet, and not 
between DMSO and enzyme28. Furthermore, Iwatani et al., showed the DMSO impact on 
epigenetic regulatory system in the mice embryonic stem cells where the compound induced 
changes in genome wide DNA methylation profile and upregulated the DNMT3A mRNA and 
protein levels29. However, the DMSO concentration was one hundred times higher than the 
concentration used in the present investigation. In addition, the authors used mice embryonic 
stem cells, which differ from hBMMSCs used in the present study and could explain the 
possibly contradictory results of decreased DNMTs activity observed by us. It is worth pointing 
out that in the present study, DNMTs activities were analyzed as a whole and, therefore, the 
DMSO effect, specifically on the DNMT3A activity, could not be assessed. It is possible that 
multipotent cells including hBMMSCs might be more prone and more sensitive to DMSO 
effects, as they maintain an undifferentiated state, compared to other cell types that present 
higher committed phenotypes. Taking previously published reports and results obtained in this 
study together the DMSO might act as a modulator of the epigenetic machinery genes and this 
possibility should be taken into account when using DMSO as a vehicle. However, since 
different concentrations were used across the studies, further investigations should be 
conducted aiming at better defining the DMSO optimal dose and concentration for modulating 
the epigenetic machinery, according to specific objectives.  
It should be underlined though that, in general, the observed RG108 effects were 
stronger than those of DMSO, even for epigenetic machinery genes. For DNMT1 and TET1 
transcript levels, for instance, RG108-promoted increase in gene expression was fifteen times 
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bigger than in DMSO only-treated cells. Furthermore, DNMTs activity levels decreased 2.5 
times more in the RG108 group, comparing to DMSO group. Most importantly, only RG108 
but not DMSO had a significant impact on pluripotency gene expression and their 
methylation/hydroxymethylation levels. Therefore, the suggested supportive role of RG108 in 
hBMMSCs-based stem cell therapies is solely due to the drug itself.  
 
CONCLUSIONS  
When used at low concentrations, RG108 is a non-toxic demethylating agent, triggering 
changes in DNA methylation/hydroxymethylation levels, enzymatic activity of epigenetic 
machinery and transcription of multipotency gene markers in hBMMSCs. The epigenetic 
modulation might be involved in the chromatin remodelling, leading to a more permissive 
chromatin state and these changes could contribute to the proposed role of RG108 in improving 
the efficacy of stem cell therapies. DMSO also triggered changes, suggesting that DMSO can 
be considered a modulator of epigenetic machinery enzymes, although with milder effect 
compared to RG108.  
 
METHODS 
Cell characteristics  
Cryopreserved human bone marrow-derived mesenchymal stem cells (hBMMSCs) 
were purchased from Lonza (Walkersville, MD, USA) at passage 2 (P2) and tested by Lonza 
for the presence of viral nucleic acid from HIV, hepatitis B virus, and hepatitis C virus. Initially, 
cells were seeded at 5,000 - 6,000 per cm2, according to manufacturer's recommendation and 
grown in complete culture medium composed of Dulbecco’s modified Eagle medium high 
glucose (DMEM), supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and 
streptomycin (100 mg/mL) (Gibco, Carlsbad, CA, USA). Cells were maintained in a humidified 
incubator at 37°C and 5 % CO2 atmosphere along all experiments.  
Only cells at passages P5 - P7 were used for the experiments and the results were 
obtained from two independent experiments. To avoid passive demethylation, cell 
synchronization was performed by serum starvation for 24 h. The age of hBMMSCs donor was 
between 20 and 22 years. In order to confirm their multipotentiality, the cells were tested for 
their ability to differentiate towards osteogenic and adipogenic tissues (data not shown).  
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RG108 preparation  
RG108 was purchased from Sigma (St. Louis, MO, USA) and dissolved in 150 µL 
DMSO (Sigma-Aldrich, St. Louis, MO, USA) to make 200 mM stock solution (Xu et al., 2013) 
and stored at -20°C until further use. For control purposes, hBMMSCs were also cultivated in 
standard medium/DMSO (RG108 vehicle).  
 
Groups  
After cell and drug characterization phase, experiments were carried out during 3 days 
and three experimental groups were defined as follows:  
-DMEM: hBMMSCs were cultivated in complete culture medium, supplemented with 
10% FBS, penicillin and streptomycin.  
- DMSO: hBMMSCs were cultivated in complete culture medium, supplemented with 
10% FBS, penicillin, streptomycin and DMSO (0.001%).  
- RG108: hBMMSCs were cultivated in complete culture medium, supplemented with 
10% FBS, penicillin, streptomycin and RG108 (50 µM).  
 
Viability Assay  
Initially, hBMMSCs were seeded at 0,5 x 104 cells/well in a 96-well plate with standard 
medium and incubated in a humidified incubator at 37°C and 5% CO2 for 24 h. After cell 
adhesion, they were cultivated for 7 days, with media change at day 3. Cells from the test group 
were cultivated with RG108 diluted in complete culture medium, at 50 µM, 100 µM 200 µM 
concentrations and 400 µM, 800 µM, 1,6 mM concentrations (data not shown). The metabolic 
activity was measured by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide 
(MTT) assay (Sigma, St. Louis, MO, USA) according to the manufacturer’s instructions. The 
absorbance of 6 wells per group was determined at 540 nm using an Elisa micro-plate reader 
(VersaMax, Molecular Devices, Sunnyvale, CA, USA). Since the cell metabolic activity was 
the least affected with 50 µM, the viability assay was repeated at day 3, with RG108 at 50 µM, 
as described above.  
 
Population doubling time assay  
To determine the population doubling time (PDT), hBMMSCs were seeded at 24 well 
plates at three different densities with standard medium. After adhesion, cells corresponding to 
the time 0 were fixed with trichloroacetic acid 5 %. The remaining cells were fixed and lysed 
with NaOH at 1, 2, 3, 4, 5, 6 and 7 days and the PDT was determined with the 
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spectrophotometric quantification at 260 nm. Aiming to determine if RG108 at 50 µM was able 
to alter the PDT of hBMMSCs, the assay was repeated in the same periods of time, as described 
above.  
 
Apoptosis assay  
Aiming to evaluate if RG108 at concentration of 50 µM could trigger cell death by 
apoptosis, 3 x 105 cells were seeded in 100 mm dishes, cultivated in complete culture medium 
and treated according to experimental groups for 3 days. Later, cells were harvested and freshly 
evaluated for apoptosis by flow cytometry using nucleic acid dye 7-Amino-Actinomycin D (7-
AAD) and phospholipid-binding protein Annexin V, as described by manufacturer’s 
instruction. Cells were measured using a FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA, USA) connected to the CellQuest software (BD Biosciences, USA).  
 
DNA, RNA and protein isolation 
hBMMSCs were seeded at 2.23 x 106 cells in 150 mm dishes in complete culture 
medium and treated according to experimental groups. Cells were scraped off in PBS, after 3 
days, and divided into three eppendorf tubes, the first for DNA extraction, the second for RNA 
extraction and the third one for protein isolation. DNA and protein tubes were stored at -80°C 
until further use. RNA tubes were quickly centrifuged in refrigerated centrifuge for pellet 
formation at 4°C and then, 1 mL of TRIzol reagent (Gibco BRL, Life Technologies, Rockville, 
MD, USA) was added to the pellet and samples were stored at -80°C until further use.  
Total RNA was isolated by TRIzol method, according to manufacturer’s 
recommendation, DNase-treated (Turbo DNA-free, Ambion Inc., Austin, TX, USA) and 1 µg 
was used for complementary DNA (cDNA) synthesis, using the First-Strand cDNA Synthesis 
Kit (Roche Diagnostic Co., Indianapolis, IN, USA). cDNA samples were stored at -20°C.  
Total DNA was purified by extraction with phenol/chloroform/isoamyl alcohol and DNA 
samples were stored at -20°C. DNA and RNA concentrations were determined using 
spectrophotometer (Nanodrop 1000; Nanodrop Technologies LLC, Wilmington, NC, USA).  
Total protein was extracted (EpiQuik Nuclear Extraction Kit I, Epigentek Group Inc., NY, 
USA) using 106 cells as input and 20 µL as a final volume. Subsequently, protein nuclear 
extracts were quantified using Pierce BCA Assay (Thermo Scientific Inc., Brenner, Germany), 
according to manufacturer’s recommendation and stored at - 80°C.  
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Global methylation assay  
Each DNA sample was plated five times for each group (100 ng DNA per well) and 
global methylation level analysis was performed using Imprint® Methylated DNA 
Quantification Kit (Sigma, St. Louis, MO, USA), according to manufacturer’s instructions at 
day 3. Positive control was used for comparison of methylation levels and the absorbance was 
read in a microplate reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA), at 450 nm.  
 
Global hydroxymethylation assay  
For global hydroxymethylation levels, the Quest 5-hmC DNA Elisa kit (Zymo Research 
Corp., Irvine, CA, USA) was used and 100 ng DNA of each sample was plated five times for 
each group, according to manufacturer’s recommendation. The control DNA set containing a 
specified percentage of 5-hmC, supplied by the manufacturer, was used for comparison 
purposes and the absorbance was read in microplate reader (VersaMax, Molecular Devices, 
Sunnyvale, CA, USA), at 450 nm.  
 
DNMTs activity/inhibition assay  
5 µg of protein nuclear extract input for each sample was used to analyze DNMTs 
activity or inhibition in duplicate measurement with EpiQuik DNA Activity/Inhibition Assay 
Ultra Kit Colorimetric (Epigentek Group Inc., NY, USA), according to manufacturer’s 
recommendation. The absorbance was read in microplate reader (VersaMax, Molecular 
Devices, Sunnyvale, CA, USA), at 450 nm.  
 
Demethylases activity/inhibition assay  
5 µg of protein nuclear extract input for each sample was used to measure the 
demethylases activity/inhibition with EpiQuik DNA Demethylase Activity/Inhibition Assay 
Ultra Kit (Epigentek Group Inc., NY, USA) in duplicate, according to manufacturer’s 
recommendation. The absorbance was read in microplate reader (VersaMax, Molecular 
Devices, Sunnyvale, CA, USA), at 450 nm.  
 
DNMT1 protein levels assay  
5 µg of protein nuclear extract input for each sample was used to measure the protein 
levels with EpiQuik DNMTs Assay Kits (Epigentek Group Inc., NY, USA), in duplicate, 
according to manufacturer’s recommendation. The absorbance was read in microplate reader 
(VersaMax, Molecular Devices, Sunnyvale, CA, USA), at 450 nm.  
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mRNA expression analysis  
The DNMT1, DNMT3B, TET1 and OCT4 mRNA expression analysis was conducted 
in a real-time polymerase chain reaction (PCR) apparatus (LightCycler 480 Real Time PCR 
System; Roche Diagnostics GmbH, Mannheim, Germany) with a SYBR Green Kit (FastStart 
Essential DNA Green Master; Roche Diagnostic Co., Indianapolis, IN, USA). Results were 
expressed as relative amounts of the target gene using β-actin as inner reference gene. The 
characteristics of primers are presented in Table 1.  
 
Quantitative PCR assay for gene specific DNA methylation and hydroxymethylation  
Genomic DNA was initially treated with T4-β-glucosyltransferase (T4-BGT) (New 
England Biolabs, Beverly, MA, USA), adding glucose moiety to 5-hmC (gDNA) to distinguish 
amongst DNA methylation and hydroxymethylation. For each sample, three tubes containing 
400 ng gDNA each were treated with 1X NE buffer 4, 40 mM UDP glucose, T4-BGT (1 unit) 
to a final volume of 20 µL and incubated at 37°C for 1 hour, followed by 10 min at 65°C. 
Subsequently, samples were digested with MspI or HpaII restriction enzymes (New England 
Biolabs, Beverly, MA, USA) or H2O (control), to a final volume of 25 µL at 37 °C for 1 hour. 
Tubes containing the HpaII restriction enzyme were submitted to additional incubation for 10 
min. at 65°C, for enzyme inactivation. After the digestion of restriction enzymes, 40 ng of 
gDNA were subjected to 40 amplification cycles using 0.5 µM of primers, annealing at proper 
temperature for each target region to a final reaction volume of 10 µL. Analyses were conducted 
in the same PCR apparatus as for RNA expression assay, also using the same SYBR Green. 
The comparative Ct method was used and samples were normalized by setting the control 
reaction as calibrator. Primers were designed on regulatory regions such as DNaseI 
hypersensitivity clusters sites, layered by histone modifications marks, CpG regions and 
transcription factors binding sites, with free primer design and analysis software30 and further 
analyzed for secondary structures and annealing temperatures by the Beacon Designer, Free 
Edition (http://www.premierbiosoft.com/). Sequences and chromosome location were 
confirmed by the in-silico PCR (https://genome.ucsc.edu/). The characteristics of primers and 
regions of genes analyzed are illustrated in Table 2.  
 
Statistical analysis  
Data were initially examined for normality by Shapiro-Wilk test and expressed as mean ± 
standard deviation (SD). One-way analysis of variance (ANOVA α ≤ 0.05) followed by 
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pairwise multiple-comparison test (Tukey) (Minitab ® 16, State College, PA, USA) were used 
to identify the difference amongst groups.  
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FIGURES 
 
 
 
 
Figure 1. Effect of RG108 on metabolism and cellular death. (a) hBMMSCs in the 
presence of RG108, at day 7, showed 32%, 16% and 12% of reduction in cell viability 
for 50 µM, 100 µM and 200 µM, respectively (p > 0.05). (b) hBMMSCs in the 
presence of RG108 (50 µM) showed similar metabolic activity amongst groups, at day 
3 without statistical difference amongst groups (p > 0.05); data are presented as mean 
and standard deviation of six wells absorbance at 450 nm, of each sample. (c) graphic 
illustrates RG108 treatment results (50 µM – 3 days), the demethylating agent did not 
affect the hBMMSCs ability to proliferate in vitro; data are presented as l(n) of cells 
seeded at three different densities and the spectrophotometric quantification at 260 nm; 
(d) graphic represents the DMEM group; (e) graphic represents the DMSO group; (f) 
graphic illustrates that the RG108 demethylating agent (50 µM) was not able to trigger 
cell death by apoptosis.  
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Figure 2. Effect of RG108 on global methylation and hydroxymethylation 
levels. (a) Graphic illustrates a significant decrease in hBMMSCs methylation 
global levels, in the RG108 group, comparing to the DMEM group (p ≤ 0.05). (b) 
Graphic illustrates the hBMMSCs hydroxymethylation global levels, without 
statistical difference amongst groups (p > 0.05). * represent significant inter-group 
differences by ANOVA One Way followed by Tukey test (p ≤ 0.05).  
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Figure 3. Effect of RG108 on DNMTs and demethylases activities and DNMT1 
protein levels. (a) Graphic illustrates significant decrease in the DNMTs activity for 
DMSO and RG108 groups; * indicates p ≤ 0.01 RG108 x DMEM groups; # indicates 
p ≤ 0.05 DMSO x DMEM groups; + indicates p ≤ 0.05 DMSO x RG108 groups. (b) 
Graphic illustrates a significant increase in the demethylases activity for DMSO and 
RG108 groups, comparing to the DMEM group; # p ≤ 0.01 amongst DMSO x DMEM 
groups; + p ≤ 0.01 amongst DMSO x RG108 groups; *p ≤ 0.01 amongst RG108 x 
DMEM groups. (c) Graphic shows reduction (%) in DNMT1 protein levels in RG108 
and DMSO groups, with no significant differences amongst groups. *, #, + indicate 
statistical difference by ANOVA One Way followed by the Tukey test (p ≤ 0.05).  
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Figure 4. Transcript levels of epigenetic machinery genes and multipotency gene 
markers DNMT1 (a), DNMT3B (b), TET1 (c) and OCT4 (d) mRNA levels were 
analyzed by qPCR after 3 days of treatment with RG108. Results correspond to mRNA 
levels ratio normalized to the ß-actin levels. Determination of gene expression relative 
levels was performed using the cycle threshold (Ct) method and the results are 
presented as mean/SD. (a) DNMT1 and DNMT3B (b) mRNA levels were significantly 
decreased for DMEM x DMSO groups, # indicate p ≤ 0.05; DMEM x RG108 groups, 
* p ≤ 0.05; DMSO x RG108 groups, + p ≤ 0.05. (c) and (d) Graphics illustrate a 
significant increase in the TET1 and OCT4 mRNA levels in the RG108 group, when 
compared to DMSO (# p ≤ 0.05) and DMEM groups (* p ≤ 0.05) without statistical 
differences amongst DMEM and DMSO groups by One-Way ANOVA followed by the 
Tukey test (p ≤ 0.05).  
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Figure 5. Epigenetic modulation of epigenetic machinery enzymes. Methylation 
and hydroxymethylation levels were analyzed by DNA glucosylation followed by 
restriction enzyme reactions and real time PCR of specific sequence in the DNMT1 
and DNMT3B genes, after 3 days of treatment with RG108. Determination of 
methylation and hydroxymethylation relative levels were performed using the cycle 
threshold (Ct) method and the methylation results are presented as HpaII levels - 
MspI levels/control levels and the hydroxymethylation results are presented as MspI 
levels/control levels. (a) Graphic illustrates that there was no statistical difference in 
the DNMT1 gene amongst groups (p > 0.05) in methylation and hydroxymethylation 
levels; (b) Graphic demonstrates significant increase in the DNMT3B methylation 
levels in DMSO (#  p ≤ 0.05) and RG108 (* p ≤ 0.05) groups, when comparing to 
the DMEM group. Non-statistical difference was detected in hydroxymethylation 
levels. *, #, + indicate statistical differences by ANOVA One Way followed by the 
Tukey test (p ≤ 0.05). 
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Figure 6. Epigenetic modulation of multipotency gene markers. Methylation and 
hydroxymethylation levels were analyzed by DNA glucosylation followed by restriction 
enzyme reactions and real time PCR of specific sequence in the NANOG and OCT4 
genes, after 3 days of treatment with RG108. Determination of methylation and 
hydroxymethylation relative levels were performed using the cycle threshold (Ct) 
method and the methylation results are presented as HpaII levels - MspI levels/control 
levels and the hydroxymethylation results are presented as MspI levels/control levels. 
(a) Graphic illustrates significant decrease in NANOG hydroxymethylation levels in the 
RG108 group when comparing to DMEM group (* p ≤ 0.05) and DMSO group (# p ≤ 
0.05). (b) Graphic demonstrates significant down modulation in OCT4 methylation and 
hydroxymethylation levels in the RG108 group (* p ≤ 0.05) when comparing to DMEM 
and DMSO groups (# p ≤ 0.05) *, # indicate statistic differences by ANOVA One Way 
followed by the Tukey test (p ≤ 0.05).  
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Figure 7. Mechanism of RG108 action in hBMMSCs. A globlal decrease in DNA 
methylation leading to a local decrease of methylation levels at the promotes of OCT4, 
TET1 and possibly NANOG. These, in turn would upregulate their expression and 
OCT4/NANOG/TET1 are well known to promote cell pluripotency. In addition, 
downregulation of DNMT1 expression (possibly through a secondary mechanism which 
could involve OCT4 and NANOG) and a possible increase in demethylases activity (due 
to increase of TET1 expression) would further enhance global loss of methylation. The 
global loss of methylation could then promote a more permissive chromatin therefore 
reinforcing the state of multipotency in hBMMScs.  
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3 CONCLUSÃO 
 
O RG108, quando usado em baixas concentrações, é um agente desmetilante não tóxico, 
capaz de promover mudanças nos níveis de metilação/hidroximetilação do DNA, na atividade 
enzimática da maquinaria epigenética e na transcrição de genes marcadores de 
multipotencialidade, em hBMMSCs. A modulação epigenética pode estar envolvida no 
remodelamento da cromatina, levando a um estado de cromatina mais permissiva e essas 
mudanças poderiam contribuir para o papel proposto para o RG108 no aumento da eficácia das 
terapias celulares. As alterações promovidas pelo DMSO sugerem que ele possa ser 
considerado um modulador da maquinaria epigenética, embora com efeito mais moderado, 
quando comparado do RG108. 
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